Market Closed -
Nyse
04:00:00 2024-06-14 pm EDT
5-day change
1st Jan Change
1.14
USD
-1.72%
+1.79%
-35.96%
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell Small Cap Comp Value Index
June 23, 2023 at 12:00 am EDT
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell Small Cap Comp Value Index
Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024
May. 10
Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 10
CI
Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q1 Revenue $3.7M, vs. Street Est of $9.2M
May. 10
MT
Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024
Mar. 14
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 14
CI
Transcript : Protalix BioTherapeutics, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Nov. 06
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 06
CI
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $10.3M
Nov. 06
MT
HC Wainwright Adjusts Protalix BioTherapeutics' Price Target to $10 From $7, Keeps Buy Rating
23-10-31
MT
Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023
23-09-11
CI
Transcript : Protalix BioTherapeutics, Inc., Q2 2023 Earnings Call, Aug 07, 2023
23-08-07
Earnings Flash (PBDA) PROTALIX BIOTHERAPEUTICS Reports Q2 Revenue $35.1M
23-08-07
MT
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-07
CI
Transcript : Protalix BioTherapeutics, Inc. - Special Call
23-06-27
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell Small Cap Comp Value Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2500 Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 3000E Value Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell Small Cap Completeness Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 3000 Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2000 Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2000 Dynamic Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 3000E Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 3000 Value Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2500 Value Index
23-06-23
CI
Protalix BioTherapeutics, Inc.(NYSEAM:PLX) added to Russell 2000 Value Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
More about the company
Last Close Price
1.14
USD
Average target price
12
USD
Spread / Average Target
+952.63%
Consensus
1st Jan change
Capi.
-35.96% 83.58M +40.80% 53.67B +35.79% 38.86B -8.05% 38.76B -8.98% 27.27B +10.69% 25.91B -16.21% 20.29B +31.00% 12.78B +28.51% 12.18B -1.67% 11.96B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1